Roivant Sciences’ (ROIV) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a report released on Friday morning, MarketBeat.com reports. HC Wainwright currently has a $41.00 price target on the stock.

A number of other analysts have also weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Tuesday, August 25th. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Guggenheim lifted their price objective on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Roivant Sciences Price Performance

Shares of ROIV opened at $34.71 on Friday. The company has a market capitalization of $25.07 billion, a P/E ratio of -65.49 and a beta of 1.12. Roivant Sciences has a one year low of $11.85 and a one year high of $37.97. The business’s 50 day simple moving average is $35.16 and its 200-day simple moving average is $30.93.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. On average, sell-side analysts anticipate that Roivant Sciences will post -2 EPS for the current fiscal year.

Insider Transactions at Roivant Sciences

In related news, insider Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75. Following the sale, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $675,364,288.75. This trade represents a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel Allen Gold sold 800,000 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the completion of the sale, the director owned 13,701,546 shares in the company, valued at $473,388,414.30. The trade was a 5.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,855,913 shares of company stock valued at $100,107,258 in the last ninety days. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its position in Roivant Sciences by 4,212.2% during the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company’s stock worth $672,448,000 after purchasing an additional 18,560,434 shares during the period. Morgan Stanley raised its position in shares of Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after purchasing an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after purchasing an additional 8,621,567 shares during the period. Norges Bank acquired a new stake in shares of Roivant Sciences during the 4th quarter worth about $112,750,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Roivant Sciences during the 4th quarter worth about $76,272,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences News Summary

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: The U.S. FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis, a rare skin and muscle disease. Roivant describes it as the first and only oral targeted therapy for the condition, and the once-daily treatment is now available in the United States. The approval provides Roivant and partner Priovant Therapeutics with a commercial product and a potential new revenue stream. Reuters FDA approval article
• Positive Sentiment: Roivant and Priovant set LISRAYA’s list price at $35,000 for a 30-day supply. The high price could support meaningful revenue if the drug achieves broad reimbursement and adoption, although the companies will still need to build commercial demand in a rare-disease market. Reuters LISRAYA pricing article
• Neutral Sentiment: HC Wainwright reaffirmed a Buy rating and established a $41 price target, implying additional upside from the reported trading level. The recommendation reinforces bullish analyst sentiment, but the target does not guarantee near-term performance. HC Wainwright analyst rating
• Negative Sentiment: The stock’s decline following the approval indicates that the regulatory win may have been anticipated or that investors are using the news to lock in gains. Attention is now shifting to launch execution, payer coverage, patient access and whether LISRAYA’s premium list price can translate into sales.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.